Smoking Cessation Sees 122% Growth as Public Seek to Reduce Risk of COVID-19 - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--ResearchAndMarkets.com published a new article on the pharmaceuticals industry, "Smoking Cessation Sees 122% Growth as Public Seek to Reduce Risk of COVID-19"

Smoking has long been established as a risk factor for respiratory disease and health officials are now reporting that smokers with COVID-19 are more likely to face serious complications. Recent studies have found that smokers with COVID-19 are 14 times more likely to need intensive care than non-smokers.

This has caused a surge in demand for smoking cessation products such as nicotine replacements and behavioral supports as people try to protect themselves and strengthen their lungs. Sales of nicotine replacement products increased by 54% in the third week of March and helplines have reported an increase in callers concerned about the coronavirus. Companies like Pivot and Quit Genius have responded to the growing interest by offering free trials of their coaching and support apps while Lucy, a seller of nicotine gum and lozenges, has seen sales rise by 75% in the past month.

To see the full article and a list of related reports on the market, visit "Smoking Cessation Sees 122% Growth as Public Seek to Reduce Risk of COVID-19"

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.